Aktiespot

Lee's Pharmaceutical Holdings Limited (Lee s Pharmaceutical Hldgs LtdR) Aktie

L1PA.F

€0.1090-0.0030 (-2.68%)
Chart wird geladen...

Lee s Pharmaceutical Hldgs LtdR

Eröffnung0.1100
Hoch0.1110
Tief0.1090
Volumen6
P/E5.45
Marktkapitalisierung67.84M
52-Wochen-Hoch0.2700
52-Wochen-Tief0.1040
Durchschn. Volumen32
Dividende4.50%
Beta0.57
EPS0.0200

Über Lee's Pharmaceutical Holdings Limited (Lee s Pharmaceutical Hldgs LtdR) Aktie

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

Unternehmensinformationen

Börse: Frankfurt (FRA)
Sektor: Sundhed
Branche: Lægemiddelproducenter – Special og generisk
Adresse:
Building 20E
Sha Tin, Hong Kong
Telefon: + 852 2314 1282

Analystenempfehlungen

Diese Übersicht gibt einen schnellen Einblick, wie Analysten das Aktienpotenzial basierend auf ihren neuesten Analysen und Kurszielen bewerten.

Niedrigstes Kursziel
Durchschnittliches Kursziel
Median Kursziel
Höchstes Kursziel

Andere sehen auch: